Who to call at Rapport Therapeutics, Inc., and when
Fundz watches for the moments Rapport Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Rapport Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rapport Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rapport Therapeutics, Inc.. With Fundz connected, it knows.
Rapport Therapeutics, Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
rapport.cloudExecutive Summary
Analysis of 8-K filing content
Rapport Therapeutics completed an underwritten public offering of 8.3 million shares at $21.00 per share, raising approximately $175 million in gross proceeds, with underwriters exercising their full over-allotment option. This capital infusion provides financial resources to support the company's operations and strategic growth objectives.
Quick answer
Rapport Therapeutics, Inc. filed a Form 8-K with the SEC on October 30, 2026 under Item 1.01 (Entry into Material Agreement). Rapport Therapeutics completed an underwritten public offering of 8.3 million shares at $21.00 per share, raising approximately $175 million in gross proceeds, with underwriters exercising their full over-allotment option.
- What did Rapport Therapeutics, Inc. disclose in its 8-K filed October 30, 2026?
- Rapport Therapeutics completed an underwritten public offering of 8.3 million shares at $21.00 per share, raising approximately $175 million in gross proceeds, with underwriters exercising their full over-allotment option. This capital infusion provides financial resources to support the company's operations and strategic growth objectives.
- What does 8-K Item 1.01 (Entry into Material Agreement) mean?
- The company signed a major contract or deal. Companies generally must file it within four business days of the event.
- Which other companies filed an 8-K Item 1.01 around the same time?
- OpenWorld, Inc. (October 30, 2026) also filed an Item 1.01 8-K within a week of Rapport Therapeutics, Inc.
- Where can I read the original Rapport Therapeutics, Inc. filing?
- The original filing is on SEC EDGAR (CIK 0002012593), accession number 0001193125-26-441851.
Source: Fundz verified event record.
Other companies that filed an 8-K Item 1.01 (Entry into Material Agreement) the same week
Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.
- OpenWorld, Inc. (October 30, 2026): OpenWorld appointed Patrick Kim as CEO of Blocksight effective October 27, 2026, following the company's merger.
Key Takeaways
Rapport raised approximately $175 million gross from the primary offering (8.3M shares × $21.00) plus additional proceeds from the full exercise of the 1.4M share over-allotment option
The offering included 1.2 million pre-funded warrants with a nominal $0.001 exercise price, providing immediate dilution and potential for additional capital upon exercise
2 more takeaways
Related Filings (1)
1 more filing from Rapport Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Rapport Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.